collection
https://read.qxmd.com/read/38364204/nintedanib-plus-chemotherapy-for-small-cell-lung-cancer-with-comorbid-idiopathic-pulmonary-fibrosis
#1
JOURNAL ARTICLE
Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Yoko Agemi, Takaaki Tokito, Kentaro Ito, Kohsuke Isomoto, Yuichi Takiguchi, Yasuto Yoneshima, Toshihide Yokoyama, Toshiyuki Harada, Shigeru Tanzawa, Nobuaki Kobayashi, Tae Iwasawa, Toshihiro Misumi, Hiroaki Okamoto
Rationale : A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small-cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF). Objectives : This study aimed to assess the safety and efficacy of carboplatin, etoposide, and nintedanib combination therapy for unresectable SCLC with comorbid IPF. Methods : The NEXT-SHIP study is a multicenter, single-arm, phase 2 trial for unresectable SCLC with IPF (registry number: jRCTs031190119). The patients received carboplatin, etoposide, and nintedanib (150 mg BID)...
February 16, 2024: Annals of the American Thoracic Society
https://read.qxmd.com/read/38329900/-radiographics-update-the-10-pillars-of-lung-cancer-screening-rationale-and-logistics-of-a-lung-cancer-screening-program
#2
JOURNAL ARTICLE
Scott J Adams, Efren J Flores, Brent P Little, Amita Sharma, Inga T Lennes, Jo-Anne O Shepard, Florian J Fintelmann
Editor's Note. - RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics . These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
March 2024: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://read.qxmd.com/read/38358935/2021-who-classification-of-lung-cancer-molecular-biology-research-and-radiologic-pathologic-correlation
#3
JOURNAL ARTICLE
Tomoaki Sasaki, Hirofumi Kuno, Takashi Hiyama, Shioto Oda, Sota Masuoka, Yusuke Miyasaka, Tetsuro Taki, Yusuke Nagasaki, Seiyu Jeong-Yoo Ohtani-Kim, Genichiro Ishii, Sawako Kaku, Girish S Shroff, Tatsushi Kobayashi
The 2021 World Health Organization (WHO) classification system for thoracic tumors (including lung cancer) contains several updates to the 2015 edition. Revisions for lung cancer include a new grading system for invasive nonmucinous adenocarcinoma that better reflects prognosis, reorganization of squamous cell carcinomas and neuroendocrine neoplasms, and description of some new entities. Moreover, remarkable advancements in our knowledge of genetic mutations and targeted therapies have led to a much greater emphasis on genetic testing than that in 2015...
March 2024: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://read.qxmd.com/read/38310751/immunotherapy-for-non-small-cell-lung-cancer
#4
REVIEW
Hiroshi Kagamu
Immune checkpoint inhibitors (ICI) bind to programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4), which suppress T-cell function and inhibit their inhibitory function, resulting in T-cell activation. ICI have been approved for a wide range of cancers, including malignant melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck cancer, Hodgkin's disease, small-cell lung cancer, malignant pleural mesothelioma, gastric cancer, esophageal cancer, breast cancer, uterine cancer, and hepatocellular carcinoma, and the number of indications continues to grow...
February 3, 2024: Respiratory Investigation
https://read.qxmd.com/read/38300206/acr-lung-rads-v2022-assessment-categories-and-management-recommendations
#5
JOURNAL ARTICLE
Jared Christensen, Ashley Elizabeth Prosper, Carol C Wu, Jonathan Chung, Elizabeth Lee, Brett Elicker, Andetta R Hunsaker, Milena Petranovic, Kim L Sandler, Brendon Stiles, Peter Mazzone, David Yankelevitz, Denise Aberle, Caroline Chiles, Ella Kazerooni
The American College of Radiology created the Lung CT Screening Reporting and Data System (Lung-RADS) in 2014 to standardize the reporting and management of screen-detected pulmonary nodules. Lung-RADS was updated to version 1.1 in 2019 and revised size thresholds for nonsolid nodules, added classification criteria for perifissural nodules, and allowed for short-interval follow-up of rapidly enlarging nodules that may be infectious in etiology. Lung-RADS v2022, released in November 2022, provides several updates including guidance on the classification and management of atypical pulmonary cysts, juxtapleural nodules, airway-centered nodules, and potentially infectious findings...
January 29, 2024: Chest
https://read.qxmd.com/read/38294292/first-line-immunotherapy-in-non-small-cell-lung-cancer-how-to-select-and-where-to-go
#6
REVIEW
Andrea Mogavero, Ornella Cantale, Veronica Mollica, Shobana Anpalakhan, Alfredo Addeo, Giannis Mountzios, Alex Friedlaender, Ravindran Kanesvaran, Silvia Novello, Giuseppe Luigi Banna
INTRODUCTION: Immunotherapy (IO) has established a new milestone in lung cancer treatment. Several registrational studies have approved immune checkpoint inhibitors (ICIs) in different settings, including the metastatic nonsmall cell lung cancer (NSCLC). As wellknown, responders are just a certain proportion of patients, therefore their selection by using predictive factors has stood out as a crucial issue to address in tailoring a patientcentered care. AREAS COVERED: In our review we propose a detailed yet handy cross section on ICIs as firstline treatment in metastatic NSCLC, regarding indications, histological, clinical and bloodbased biomarkers, other than their mechanisms of resistance and new immunological actionable targets...
January 31, 2024: Expert Review of Respiratory Medicine
https://read.qxmd.com/read/38279776/lung-cancer-statistics-2023
#7
JOURNAL ARTICLE
Tyler B Kratzer, Priti Bandi, Neal D Freedman, Robert A Smith, William D Travis, Ahmedin Jemal, Rebecca L Siegel
Despite decades of declining mortality rates, lung cancer remains the leading cause of cancer death in the United States. This article examines lung cancer incidence, stage at diagnosis, survival, and mortality using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Over the past 5 years, declines in lung cancer mortality became considerably greater than declines in incidence among men (5...
January 27, 2024: Cancer
https://read.qxmd.com/read/38227033/perioperative-toripalimab-plus-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-the-neotorch-randomized-clinical-trial
#8
RANDOMIZED CONTROLLED TRIAL
Shun Lu, Wei Zhang, Lin Wu, Wenxiang Wang, Peng Zhang, Wentao Fang, Wenqun Xing, Qixun Chen, Lin Yang, Jiandong Mei, Lijie Tan, Xiaohong Sun, Shidong Xu, Xiaohua Hu, Guohua Yu, Dongliang Yu, Nong Yang, Yuping Chen, Jinlu Shan, Ligang Xing, Hui Tian, Xun Zhang, Ming Zhou, Haohui Fang, Guowu Wu, Yunpeng Liu, Minhua Ye, Lejie Cao, Jie Jiang, Xingya Li, Liangming Zhu, Danqing Li, Mingqiang Kang, Aihong Zhong, Keneng Chen, Nan Wu, Qian Sun, Haitao Ma, Kaican Cai, Changli Wang, Gen Lin, Kunshou Zhu, Yu Zhang, Xiaochun Zhang, Hong Hu, Wengang Zhang, Jun Chen, Zhixiong Yang, Xiaosheng Hang, Jian Hu, Yunchao Huang, Zhiye Zhang, Lumin Zhang, Liwei Zhang, Lunxu Liu, Dongmei Lin, Jie Zhang, Gang Chen, Yuan Li, Lei Zhu, Weihua Wang, Wenbo Yu, Dezhen Cao, Patricia Keegan, Sheng Yao
IMPORTANCE: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. OBJECTIVE: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone...
January 16, 2024: JAMA
https://read.qxmd.com/read/38195910/lung-cancer-in-patients-who-have-never-smoked-an-emerging-disease
#9
REVIEW
Jaclyn LoPiccolo, Alexander Gusev, David C Christiani, Pasi A Jänne
Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of diagnoses, smoking rates have been decreasing for several decades. Lung cancer in individuals who have never smoked (LCINS) is estimated to be the fifth most common cause of cancer-related deaths worldwide in 2023, preferentially occurring in women and Asian populations. As smoking rates continue to decline, understanding the aetiology and features of this disease, which necessitate unique diagnostic and treatment paradigms, will be imperative...
February 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38172024/advances-in-the-diagnosis-and-treatment-of-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutation
#10
REVIEW
Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
The discovery of epidermal growth factor receptor (EGFR) mutations has greatly changed the clinical outlook for patients with advanced non-small-cell lung cancer (NSCLC). Unlike the most common EGFR mutations, such as exon 19 deletion (del19) and exon 21 L858R point mutation, EGFR exon 20 insertion mutation (EGFR ex20ins) is a rare mutation of EGFR. Due to its structural specificity, it exhibits primary resistance to traditional epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), leading to poor overall survival prognosis for patients...
November 23, 2023: Clinical Lung Cancer
https://read.qxmd.com/read/38153722/rapid-advances-in-resectable-non-small-cell-lung-cancer-a-narrative-review
#11
JOURNAL ARTICLE
Howard Jack West, Jae Y Kim
IMPORTANCE: A series of high-profile clinical trials for patients with resectable early-stage non-small cell lung cancer (NSCLC) have recently changed the standard of care in this setting. Specifically, studies have demonstrated statistically and clinically significant improvements in efficacy with the targeted therapy for adjuvant osimertinib in patients with resected NSCLC harboring an epidermal growth factor receptor (EGFR) genomic abnormality (GA), whereas trials with chemotherapy combined with nivolumab in the neoadjuvant setting and others testing atezolizumab or pembrolizumab as adjuvant therapy have all demonstrated improvements in event-free survival (EFS) (for neoadjuvant therapy) or disease-free survival (DFS) (for adjuvant therapy)...
December 28, 2023: JAMA Oncology
https://read.qxmd.com/read/38071759/a-rare-case-of-hepatoid-adenocarcinoma-of-the-lung
#12
JOURNAL ARTICLE
Xuejian Sun, Jialin Liu, Ting Hu, Yefan Wu, Hao Zhang
Hepatoid adenocarcinoma of the lung is a special type of primary origin in the lung with obvious pathological features and short survival time. However, standard treatment guidelines have not yet been established. Herein, we report a case of hepatoid adenocarcinoma with the primary lesion located in the left upper lung. The tumour size was reduced after four cycles of combined therapy. Subsequent postoperative pathology confirmed complete remission.
December 10, 2023: Clinical Respiratory Journal
https://read.qxmd.com/read/37806735/update-on-lung-cancer-screening-guideline
#13
REVIEW
Priyanka Senthil, Sangkavi Kuhan, Alexandra L Potter, Chi-Fu Jeffrey Yang
Lung cancer screening has been shown to reduce lung cancer mortality and is recommended for individuals meeting age and smoking history criteria. Despite the expansion of lung cancer screening guidelines in 2021, racial/ethnic and sex disparities persist. High-risk racial minorities and women are more likely to be diagnosed with lung cancer at younger ages and have lower smoking histories when compared with White and male counterparts, resulting in higher rates of ineligibility for screening. Risk prediction models, biomarkers, and deep learning may help refine the selection of individuals who would benefit from screening...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806736/building-a-lung-cancer-screening-program
#14
REVIEW
Neel P Chudgar, Brendon M Stiles
Lung cancer screening improves lung-cancer specific and potentially overall survival; however, uptake rates are concerningly low. Several barriers to screening exist and require a systemic approach to address. The authors describe their approach toward building a centralized lung cancer screening program at an urban academic center along with lessons learned. To this end, the identification of involved stakeholders, evaluation of community barriers and needs, optimization of the electronic health system, and implementation of system of standardized follow-up for patients are processes for consideration...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806741/asian-perspective-on-lung-cancer-screening
#15
REVIEW
Takahiro Mimae, Morihito Okada
Lung cancer is the leading cause of cancer-related mortality in Japan and worldwide. Early detection of lung cancer is an important strategy for decreasing mortality. Advances in diagnostic imaging have made it possible to detect lung cancer at an early stage in medical practice. Conversely, screening of asymptomatic healthy populations is recommended only when the evidence shows the benefits of regular intervention. Due to a variety of evidence and racial differences, screening methods vary from country to country...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806740/lung-cancer-screening-the-european-perspective
#16
REVIEW
Piergiorgio Muriana, Francesca Rossetti, Pierluigi Novellis, Giulia Veronesi
Several randomized and observational studies on lung cancer screening held in Europe significantly contributed to the knowledge on low-dose computed tomography screening targets in high-risk individuals with smoking history and older than 50 years. In particular, steps forward have been made in the field of risk modeling, screening interval, diagnostic protocol with volumetry, optimization, overdiagnosis estimation, oncological outcome, oncological risk due to radiation exposure, recruitment, and communication strategy...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806742/artificial-intelligence-and-machine-learning-in-lung-cancer-screening
#17
REVIEW
Scott J Adams, Peter Mikhael, Jeremy Wohlwend, Regina Barzilay, Lecia V Sequist, Florian J Fintelmann
Recent advances in artificial intelligence and machine learning (AI/ML) hold substantial promise to address some of the current challenges in lung cancer screening and improve health equity. This article reviews the status and future directions of AI/ML tools in the lung cancer screening workflow, focusing on determining screening eligibility, radiation dose reduction and image denoising for low-dose chest computed tomography (CT), lung nodule detection, lung nodule classification, and determining optimal screening intervals...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806743/liquid-biopsy-as-an-adjunct-to-lung-screening-imaging
#18
REVIEW
Nathaniel Deboever, Edwin J Ostrin, Mara B Antonoff
Current lung cancer screening protocols use low-dose computed tomography scans in selected high-risk individuals. Unfortunately, utilization is low, and the rate of false-positive screens is high. Peripheral biomarkers carry meaningful promise in diagnosing and monitoring cancer with added potential advantages reducing invasive procedures and improving turnaround time. Herein, the use of such blood-based assays is considered as an adjunct to further utilization and accuracy of lung cancer screening.
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37806744/clinical-adjuncts-to-lung-cancer-screening-a-narrative-review
#19
REVIEW
Cynthia J Susai, Jeffrey B Velotta, Lori C Sakoda
The updated US Preventive Services Task Force guidelines on lung cancer screening have significantly expanded the population of screening eligible adults, among whom the balance of benefits and harms associated with lung cancer screening vary considerably. Clinical adjuncts are additional information and tools that can guide decision-making to optimally screen individuals who are most likely to benefit. Proposed adjuncts include integration of clinical history, risk prediction models, shared-decision-making tools, and biomarker tests at key steps in the screening process...
November 2023: Thoracic Surgery Clinics
https://read.qxmd.com/read/37984107/long-term-survival-of-patients-with-advanced-non-small-cell-lung-cancer-treated-using-immune-checkpoint-inhibitors
#20
REVIEW
Akihiro Tamiya
Lung cancer is the leading cause of cancer-related deaths worldwide and has a high incidence of metastasis. For patients with advanced non-small cell lung cancer (NSCLC) without targetable genomic driver mutation, the development of specific antibodies called immune checkpoint inhibitors (ICIs) against the programmed death-1 receptor, its partner programmed death ligand-1, and the cytotoxic T-lymphocyte-associated protein 4 receptor have proved more effective than standard therapies in phase III trials and have led to unprecedented prolonged survival in the first-line setting...
November 18, 2023: Respiratory Investigation
label_collection
label_collection
5851
1
2
2023-12-17 05:40:34
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.